Literature DB >> 24415962

Current clinical indications for plerixafor.

Stefan Fruehauf1.   

Abstract

Autologous and allogeneic hematopoietic stem cell (HSC) transplantation are considered the standard of care for many malignancies including lymphoma, multiple myeloma, and some leukemias. In many cases, mobilized peripheral blood has become the preferred source for HSCs. Plerixafor, an inhibitor of the interaction between CX chemokine receptor 4 (CXCR4) and stromal derived factor-1 alpha (SDF-1), has been evaluated in clinical trials and approved by the FDA and EMA. This agent has very modest toxicity and appears to be quite potent at HSC mobilization. Current clinical indications for the use of plerixafor are the subject of this review.

Entities:  

Keywords:  Allogeneic transplant; Autologous transplant; Chemomobilization; Graft characteristics; Plerixafor

Year:  2013        PMID： 24415962      PMCID： PMC3776405          DOI： 10.1159/000354229

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN： 1660-3796            Impact factor:   3.747


  43 in total

1.  Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.

Authors:  E Jantunen; V Varmavuo; A Juutilainen; T Kuittinen; E Mahlamäki; P Mäntymaa; T Nousiainen
Journal:  Ann Hematol       Date:  2012-07       Impact factor: 3.673

Review 2.  How I treat patients who mobilize hematopoietic stem cells poorly.

Authors:  L Bik To; Jean-Pierre Levesque; Kirsten E Herbert
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

Review 3.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

Review 4.  Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes.

Authors:  Stefan Fruehauf; Guido Tricot
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-07       Impact factor: 5.742

5.  Adoptive immunotherapy of acute leukemia: experimental and clinical results.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; A Cattan; M Schneider
Journal:  Cancer Res       Date:  1965-10       Impact factor: 12.701

6.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

7.  Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy.

Authors:  C A Juttner; L B To; D N Haylock; A Branford; R J Kimber
Journal:  Br J Haematol       Date:  1985-12       Impact factor: 6.998

8.  Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

Authors:  M J Dugan; R T Maziarz; W I Bensinger; A Nademanee; J Liesveld; K Badel; C Dehner; C Gibney; G Bridger; G Calandra
Journal:  Bone Marrow Transplant       Date:  2009-06-01       Impact factor: 5.483

9.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.

Authors:  R Haas; R Möhle; S Frühauf; H Goldschmidt; B Witt; M Flentje; M Wannenmacher; W Hunstein
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

10.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  13 in total

1.  Hematopoietic growth factors in transfusion medicine and cellular therapy - part I.

Authors:  Peter Schlenke; Andreas Humpe
Journal:  Transfus Med Hemother       Date:  2013-08       Impact factor: 3.747

2.  Protecting the Health and Safety of Cell and Tissue Donors.

Authors:  David F Stroncek; Lee England
Journal:  ISBT Sci Ser       Date:  2015-04-01

3.  CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Authors:  Aftab Ullah; Kaikai Wang; Pengkai Wu; David Oupicky; Minjie Sun
Journal:  Int J Nanomedicine       Date:  2019-04-26

Review 4.  Consider the chemokines: a review of the interplay between chemokines and T cell subset function.

Authors:  Marianne Strazza; Adam Mor
Journal:  Discov Med       Date:  2017-08       Impact factor: 2.970

Review 5.  The pathogenic role of angiogenesis in rheumatoid arthritis.

Authors:  Hatem A Elshabrawy; Zhenlong Chen; Michael V Volin; Shalini Ravella; Shanti Virupannavar; Shiva Shahrara
Journal:  Angiogenesis       Date:  2015-07-22       Impact factor: 9.596

Review 6.  Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.

Authors:  Francisco Rodríguez; Pablo Caruana; Noa De la Fuente; Pía Español; María Gámez; Josep Balart; Elisa Llurba; Ramón Rovira; Raúl Ruiz; Cristina Martín-Lorente; José Luis Corchero; María Virtudes Céspedes
Journal:  Biomolecules       Date:  2022-06-04

7.  Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF.

Authors:  A A Maschan; D N Balashov; E E Kurnikova; P E Trakhtman; E V Boyakova; E V Skorobogatova; G A Novichkova; M A Maschan
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

8.  Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Authors:  Marc-Andrea Baertsch; Katharina Kriegsmann; Petra Pavel; Thomas Bruckner; Michael Hundemer; Mark Kriegsmann; Anthony D Ho; Hartmut Goldschmidt; Patrick Wuchter
Journal:  Transfus Med Hemother       Date:  2017-10-04       Impact factor: 3.747

Review 9.  Novel targeted therapies for eosinophil-associated diseases and allergy.

Authors:  Susanne Radonjic-Hoesli; Peter Valent; Amy D Klion; Michael E Wechsler; Hans-Uwe Simon
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-17       Impact factor: 13.820

Review 10.  Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update.

Authors:  Yavuz M Bilgin
Journal:  J Blood Med       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.